Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Subscribe To Our Newsletter & Stay Updated
